Bio-Rad Laboratories, Inc. (NYSE:BIO) has earned an average rating of “Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $277.75.

A number of research analysts recently issued reports on BIO shares. Zacks Investment Research upgraded Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a report on Tuesday, November 7th. TheStreet upgraded Bio-Rad Laboratories from a “c+” rating to a “b-” rating in a report on Monday, November 13th. Deutsche Bank restated a “buy” rating and set a $255.00 price target on shares of Bio-Rad Laboratories in a report on Monday, September 18th. Finally, Wells Fargo & Company restated an “outperform” rating and set a $290.00 price target (up previously from $250.00) on shares of Bio-Rad Laboratories in a report on Wednesday, November 29th.

In other Bio-Rad Laboratories news, EVP Giovanni Magni sold 2,400 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $253.01, for a total transaction of $607,224.00. Following the transaction, the executive vice president now owns 9,251 shares in the company, valued at approximately $2,340,595.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP James R. Stark sold 746 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $270.51, for a total value of $201,800.46. The disclosure for this sale can be found here. Insiders have sold a total of 4,146 shares of company stock worth $1,067,414 in the last quarter. Company insiders own 28.29% of the company’s stock.

Several hedge funds have recently bought and sold shares of the business. BlackRock Inc. grew its holdings in shares of Bio-Rad Laboratories by 0.3% during the 2nd quarter. BlackRock Inc. now owns 1,738,431 shares of the medical research company’s stock worth $393,424,000 after acquiring an additional 5,320 shares during the period. Vanguard Group Inc. grew its holdings in shares of Bio-Rad Laboratories by 0.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,679,405 shares of the medical research company’s stock worth $380,067,000 after acquiring an additional 6,131 shares during the period. FMR LLC boosted its position in shares of Bio-Rad Laboratories by 237.4% in the 2nd quarter. FMR LLC now owns 711,313 shares of the medical research company’s stock worth $160,978,000 after purchasing an additional 500,513 shares in the last quarter. TimesSquare Capital Management LLC boosted its position in shares of Bio-Rad Laboratories by 7.0% in the 3rd quarter. TimesSquare Capital Management LLC now owns 665,100 shares of the medical research company’s stock worth $147,799,000 after purchasing an additional 43,450 shares in the last quarter. Finally, American Century Companies Inc. bought a new stake in shares of Bio-Rad Laboratories in the 3rd quarter worth approximately $125,820,000. Hedge funds and other institutional investors own 63.91% of the company’s stock.

Shares of Bio-Rad Laboratories (BIO) traded up $0.17 during trading hours on Friday, reaching $253.35. The company had a trading volume of 180,400 shares, compared to its average volume of 179,499. Bio-Rad Laboratories has a 52 week low of $177.68 and a 52 week high of $273.87. The stock has a market cap of $7,535.40, a P/E ratio of 80.38, a PEG ratio of 3.78 and a beta of 0.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.77 and a current ratio of 4.06.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.37. Bio-Rad Laboratories had a return on equity of 3.44% and a net margin of 1.15%. The company had revenue of $535.00 million for the quarter, compared to the consensus estimate of $507.99 million. During the same quarter in the previous year, the business earned $0.62 EPS. Bio-Rad Laboratories’s revenue was up 5.2% compared to the same quarter last year. equities research analysts anticipate that Bio-Rad Laboratories will post 2.68 earnings per share for the current fiscal year.

Bio-Rad Laboratories declared that its Board of Directors has initiated a share repurchase plan on Tuesday, November 28th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the medical research company to reacquire shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.

WARNING: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/13/bio-rad-laboratories-inc-bio-receives-273-33-consensus-price-target-from-brokerages.html.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Stock Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related stocks with our FREE daily email newsletter.